Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease research has often focused on the molecular brain changes that promote memory loss and other dementia‐related cognitive impairments. Many studies, for example, have used positron emission tomography (PET) imaging to measure brain levels of the beta‐amyloid protein, a key molecular suspect in Alzheimer's. In recent years, PET scans have become more prominent in clinical settings. Clinicians may use a positive PET scan—that is, a significant presence of beta‐amyloid plaques in the brain—to help determine a diagnosis of Alzheimer's disease. Yet, because beta‐amyloid PET remains a fairly new diagnostic tool, physicians and patients still have many basic questions about how and why it is used. This article addresses some of those questions. It explains what PET scans actually show, how they are employed in research and clinical trials, and when they should and should not be used to help diagnose Alzheimer's in everyday patients. The article also discusses whether cognitively healthy people should request PET scans to assess their risk for developing dementia. Information in the text will be updated in future years, as diagnostic imaging techniques for Alzheimer's disease continue to evolve.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Montine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894 · cited 1×
“Brain beta-amyloid PET imaging can detect betaamyloid plaques in the brain, a pathological hallmark of AD [2].”
BackgroundTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 1×
“In various studies, as many as 15 percent to 25 percent of individuals who are diagnosed with AD dementia based on clinical symptoms (not brain PET imaging) do not have evidence of elevated beta-amyloid levels on PET imaging [8,9,18].”
BackgroundSelf-citationAmyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986 · cited 2×
“In various studies, as many as 15 percent to 25 percent of individuals who are diagnosed with AD dementia based on clinical symptoms (not brain PET imaging) do not have evidence of elevated beta-amyloid levels on PET imaging [8,9,18].”
BackgroundPost-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933
Clark, C. M., Pontecorvo, M. J., Beach, T. G., Bedell, B. J., Coleman, R. E., Doraiswamy, P. M., Fleisher, A. S., Reiman, E. M., Sabbagh, M. N., Sadowsky, C. H., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70142-4 · Cited by 855
Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807
Chien, D. T., Bahri, S., Szardenings, A. K., Walsh, J. C., Mu, F., Su, M.-Y., Shankle, W. R., Elizarov, A., & Kolb, H. C. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122059 · Cited by 651
[ 18 F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease
Xia, C., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., Lam, C., Liang, Q., Liu, C., Mocharla, V. P., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.008 · Cited by 605
Johnson, K. A., Minoshima, S., Bohnen, N. I., Donohoe, K. J., Foster, N. L., Herscovitch, P., Karlawish, J. H., Rowe, C. C., Carrillo, M. C., Hartley, D. M., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.120618 · Cited by 329
Self-citation
Cited by
Chételat, G., Arbizu, J., Barthel, H., Garibotto, V., Law, I., Morbelli, S., van de Giessen, E., Agosta, F., Barkhof, F., Brooks, D. J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30314-8 · Cited by 526
Self-citationRabinovici, G. D. (2019) · Continuum · doi:10.1212/con.0000000000000700 · Cited by 170
Self-citationZhang, H., Ni, M., Yang, Y., Xie, F., Wang, W., He, Y., Chen, W., & Chen, Z. (2025) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2024.107085 · Cited by 34
Zhang, H., Wang, M., Zhou, Y., Bao, S., Wang, F., & Li, C. (2024) · Marine Drugs · doi:10.3390/md22100469 · Cited by 16
“Astaxanthin has anti-inflammatory effects on a variety of diseases, such as Alzheimer’s disease, diabetes, acute kidney injury, cardiovascular disease, and pancreatic cancer [32–35].”
Background
Metadata
- Authors
- Rabinovici, G. D., Karlawish, J., Knopman, D., Snyder, H. M., Sperling, R., & Carrillo, M. C.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2016-04
- Volume
- 12
- Issue
- 4
- Pages
- 510-515
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2341926217
- Cited by
- 36
- References
- 8
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary. https://app.cochat.ai/papers/10.1016/j.jalz.2016.03.002
- The paper
- Rabinovici, G. D., Karlawish, J., Knopman, D., Snyder, H. M., Sperling, R., & Carrillo, M. C. (2016). Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2016.03.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.